|1.||O'Connor, Mark J: 5 articles (10/2011 - 06/2008)|
|2.||Carmichael, James: 4 articles (08/2013 - 02/2012)|
|3.||Lau, Alan: 4 articles (02/2011 - 06/2008)|
|4.||Martin, Niall M B: 3 articles (05/2009 - 06/2008)|
|5.||Macpherson, Euan: 2 articles (08/2012 - 04/2012)|
|6.||Matulonis, Ursula: 2 articles (04/2012 - 02/2012)|
|7.||Gourley, Charlie: 2 articles (04/2012 - 02/2012)|
|8.||Vergote, Ignace: 2 articles (04/2012 - 02/2012)|
|9.||Friedlander, Michael: 2 articles (04/2012 - 02/2012)|
|10.||Safra, Tamar: 2 articles (04/2012 - 02/2012)|
03/01/2012 - "A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors."
02/01/2010 - "Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. "
05/01/2009 - "Daily exposure to AZD2281 for 28 days caused significant regression or growth inhibition in 46 of 52 tumors. "
11/04/2008 - "Treatment of tumor-bearing mice with AZD2281 inhibited tumor growth without signs of toxicity, resulting in strongly increased survival. "
06/15/2008 - "Treatment of these cell lines with 11 different anticancer drugs or with gamma-irradiation showed that AZD2281, a novel and specific PARP inhibitor, caused the strongest differential growth inhibition of BRCA2-deficient versus BRCA2-proficient mammary tumor cells. "
|2.||Breast Neoplasms (Breast Cancer)
07/01/2015 - "In conclusion, our data provide the first evidence of PARP inhibitor AZD2281 autophagy and mitophagy in breast cancer cell lines with BRCA mutations or BRCA-allelic loss. "
07/01/2015 - "AZD2281 treatment also resulted in growth inhibition ranging from 20 to 50% in cells with BRCA1 allelic loss, including ER(+), HER2/Neu(+) and triple-negative breast cancer (TNBC) cells, but showed no effect in cells without with type BRCA without allelic loss. "
07/01/2015 - "The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells."
11/04/2008 - "To evaluate PARP1 inhibition in a realistic in vivo setting, we tested the PARP inhibitor AZD2281 in a genetically engineered mouse model (GEMM) for BRCA1-associated breast cancer. "
09/15/2012 - "HER2 overexpression in HER2 negative breast cancer cells was sufficient to render cells susceptible to the PARP inhibitors ABT-888 and AZD-2281 both in vitro and in vivo, which was abrogated by HER2 reduction. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
|4.||Ovarian Neoplasms (Ovarian Cancer)
12/01/2011 - "From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased. "
01/01/2015 - "Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. "
02/01/2012 - "Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. "
09/01/2010 - "Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). "
02/15/2011 - "To investigate synthetic lethality in vivo, we established a BRCA2 germline-mutated xenograft model that was developed directly from human ovarian cancer tissue, treated with the PARP inhibitor olaparib (AZD2281) alone and in combination with carboplatin. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
06/28/2014 - "In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. "
06/28/2014 - "Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer."
12/15/2011 - "Thus, we hypothesized that inhibition of HRR (mediated by Chk1 via AZD7762) and PARP1 [via olaparib (AZD2281)] would selectively sensitize p53 mutant pancreatic cancer cells to radiation. "
|1.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|4.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|5.||erlotinib (CP 358,774)
|6.||2- ((R)- 2- methylpyrrolidin- 2- yl)- 1H- benzimidazole- 4- carboxamide
|9.||3- (carbamoylamino)- 5- (3- fluorophenyl)- N- (3- piperidyl)thiophene- 2- carboxamide
|2.||Heterologous Transplantation (Xenotransplantation)